There are currently 22 active clinical trials seeking participants for Atopic Dermatitis research studies. The states with the highest number of trials for Atopic Dermatitis participants are .
BROadband vs Narrowband photoTherapy for Eczema Trial Nested in the CACTI Cohort
NCT04818138
Recruiting
Atopic dermatitis (eczema) is a complicated skin condition. In fact, it represents many different underlying problems. These include abnormalities in the skin barrier, the immune system and the ability to handle different bacteria. Despite many recent gains in the understanding of eczema, a lot needs to be learned. There is little evidence to select between some of the older treatments that are available now. Even the newest targeted therapy does not clear most patients' skin. In order to improv... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/14/2025
Locations: Women's College Hospital, Toronto, Ontario
Conditions: Atopic Dermatitis, Skin Diseases, Eczema
Register for Updates
A Study to Evaluate Microneedle-based Collection of Dermal Interstitial Skin Fluid in Healthy Participants and Atopic Dermatitis Participants
NCT06934980
Recruiting
The purpose of this study is to evaluate microneedle-based collection of dermal interstitial skin fluid (dISF) in healthy participants and atopic dermatitis (AD) participants
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
07/09/2025
Locations: Innovaderm Research Inc., Montreal, Quebec
Conditions: Atopic Dermatitis, Healthy Volunteers
Register for Updates
A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In People Who Have Moderate To Severe Atopic Dermatitis
NCT05995964
Recruiting
The purpose of this study is to learn about the safety and effects of 2 study medicines (PF-07275315 and PF-07264660) for the treatment of atopic dermatitis (AD). AD is a long- lasting itchy red rash, caused by a skin reaction. This study is seeking participants who: * are 18 years of age or more. * Were confirmed to have AD at least 6 months ago. * Are not having an effective treatment result from medicines that are applied on skin for AD. * Are considered by their doctors to have moderate to... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/23/2025
Locations: Allervie Clinical Research, Birmingham, Alabama +95 locations
Conditions: Atopic Dermatitis
Register for Updates
A Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children and Infants With Moderate-to-severe Atopic Dermatitis
NCT06311682
Recruiting
The purpose of this trial is to test whether treatment with tralokinumab (administered subcutaneous injections \[SC\]) in combination with topical corticosteroids (TCS) is safe and effective to treat moderate-to-severe atopic dermatitis (AD) in children and infants. This will be judged by a range of assessments that rate the severity and extent of atopic dermatitis and its symptoms, as well as general health status and quality of life. The trial will last for up to 4 years. There will be visits... Read More
Gender:
ALL
Ages:
Between 6 months and 11 years
Trial Updated:
05/15/2025
Locations: Leo Pharma Investigational site, Birmingham, Alabama +62 locations
Conditions: Atopic Dermatitis
Register for Updates
A Longitudinal Observational Study of Patients Undergoing Therapy for IMISC
NCT03661866
Recruiting
TARGET-DERM is a longitudinal, observational study of adult and pediatric patients being managed for Atopic Dermatitis and other Immune-Mediated Inflammatory Skin Conditions (IMISC) in usual clinical practice. TARGET-DERM will create a research registry of patients with IMISC within academic and community real-world practices in order to assess the safety and effectiveness of current and future therapies.
Gender:
ALL
Ages:
All
Trial Updated:
05/02/2025
Locations: Clear Dermatology & Aesthetics Center/Investigative MD, Scottsdale, Arizona +62 locations
Conditions: Atopic Dermatitis, Hidradenitis Suppurativa, Vitiligo, Psoriasis, Alopecia Areata, Chronic Spontaneous Urticaria
Register for Updates
Characterization of Chronic Hand Eczema
NCT05026554
Recruiting
Prospective longitudinal study to characterize Choronic Hand Eczema (CHE) subtypes and Atopic Dermatitis (AD) with noninvasive molecular and imaging techniques, and assess changes through time and its association with quality of life.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
04/29/2025
Locations: Innovaderm Research, Montreal, Quebec
Conditions: Chronic Hand Eczema, Atopic Dermatitis
Register for Updates
A 32-week Trial to Evaluate the Efficacy and Safety of Tralokinumab in Subjects With Moderate-to-severe Atopic Hand Eczema Who Are Candidates for Systemic Therapy
NCT05958407
Recruiting
The purpose of this study is to test if treatment with tralokinumab is safe and effectful to treat moderate-to-severe atopic hand eczema. This will be judged by a range of assessments that rate the severity and extent of atopic hand eczema and its symptoms, as well as general health status and quality of life. The trial will last for up to 40 weeks. There will be up to 15 visits, 3 of which will be conducted by phone. The first part of the trial is called a screening period and will last up to... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/21/2025
Locations: LEO Pharma Investigational Site, Birmingham, Alabama +75 locations
Conditions: Atopic Dermatitis, Atopic Hand Eczema
Register for Updates
Collection of Samples From Subjects With Various Skin Conditions and Healthy Volunteers
NCT05994976
Recruiting
The purpose of the study is to collect different samples for molecular characterization of inflammatory skin diseases.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/29/2025
Locations: Innovaderm Research Inc., Montréal, Quebec
Conditions: Acne, Atopic Dermatitis, Chronic Hand Eczema, Hidradenitis Suppurativa, Plaque Psoriasis, Palmoplantar Pustulosis
Register for Updates
Study of Eblasakimab in Male or Female Moderate-to-Severe Atopic Dermatitis Patients Previously Treated With Dupilumab
NCT05694884
Recruiting
Multicenter, randomized, double-blind, placebo-controlled, parallel arm clinical study designed to evaluate the efficacy and safety of eblasakimab in participants with moderate-to-severe atopic dermatitis (AD) previously treated with dupilumab.The study consists of a 16-week treatment period and an 8-week follow-up period up to Week 24. Eligible participants will be randomized into one of the 2 treatment arms.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/17/2024
Locations: ASLAN Investigative Site, Birmingham, Alabama +26 locations
Conditions: Atopic Dermatitis
Register for Updates
The Therapeutic Effects of Topical Cannabidiol (CBD) Products for Atopic Dermatitis
NCT06022874
Recruiting
The goal of this observational study is to learn about the potential therapeutic effects of topical CBD products produced by Phoilex Ltd., specifically the Releaf Gel, in those diagnosed with atopic dermatitis. Patients will be routinely assessed via questionnaire, and physical measurements will be taken with respect to the affected area studied in order to judge clinical efficacy. The main question\[s\] it aims to answer are: * Did you experience an immediate increase in skin hydration? * Did... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/28/2023
Locations: Phoenix Medical Spa X Peak Human, Brampton, Ontario
Conditions: Atopic Dermatitis
Register for Updates